These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36997030)

  • 101. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
    Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
    Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (DLBCL NOS) Presenting as Multiple Subcutaneous Nodules: An Unusual Cutaneous Presentation of Systemic Disease.
    Tavberidze N; Bennett DD; Matson DR
    Case Rep Pathol; 2023; 2023():2960965. PubMed ID: 37822715
    [TBL] [Abstract][Full Text] [Related]  

  • 103. CD5+ Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Presenting as an Asymptomatic Nodule.
    Xiao A; Beatty CJ; Choudhary S; Akilov OE
    Hematol Rep; 2023 Sep; 15(3):513-517. PubMed ID: 37754668
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type: A case series and review of the literature.
    Winkler M; Albrecht JD; Sauer C; Kordaß T; Guenova E; Livingstone E; Wobser M; Mitteldorf C; Géraud C; Nicolay JP
    J Dermatol; 2024 Sep; 51(9):1233-1239. PubMed ID: 39031169
    [TBL] [Abstract][Full Text] [Related]  

  • 105. A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL).
    Martínez-Banaclocha N; Martínez-Madueño F; Caballé B; Badia J; Blanes M; Bujanda DA; Calvo V; Gómez Codina J; Blanco CQ; Espinosa P; Lavernia J; Arroyo FRG; Risueño MG; Llorca C; Cumeras R; Pulla MP; Gumà J
    Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473391
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies.
    Flümann R; Hansen J; Pelzer BW; Nieper P; Lohmann T; Kisis I; Riet T; Kohlhas V; Nguyen PH; Peifer M; Abedpour N; Bosco G; Thomas RK; Kochanek M; Knüfer J; Jonigkeit L; Beleggia F; Holzem A; Büttner R; Lohneis P; Meinel J; Ortmann M; Persigehl T; Hallek M; Calado DP; Chmielewski M; Klein S; Göthert JR; Chapuy B; Zevnik B; Wunderlich FT; von Tresckow B; Jachimowicz RD; Melnick AM; Reinhardt HC; Knittel G
    Blood Cancer Discov; 2023 Jan; 4(1):78-97. PubMed ID: 36346827
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Cutaneous B-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.
    Hristov AC; Tejasvi T; Wilcox RA
    Am J Hematol; 2020 Oct; 95(10):1209-1213. PubMed ID: 32815650
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Differences in mutational signature of diffuse large B-cell lymphomas according to the primary organ.
    Koh HH; Yoon SE; Kim SJ; Kim WS; Cho J
    Cancer Med; 2023 Oct; 12(19):19732-19743. PubMed ID: 37706649
    [TBL] [Abstract][Full Text] [Related]  

  • 109. The impact of MYD88 and PIM1 in mature large B-cell non-Hodgkin lymphomas: Defining element of their evolution and prognosis.
    Cristian M; Așchie M; Mitroi AF; Deacu M; Boșoteanu M; Bălțătescu GI; Stoica AG; Nicolau AA; Enciu M; Crețu AM; Caloian AD; Orășanu CI; Poinăreanu I
    Medicine (Baltimore); 2024 Feb; 103(6):e36269. PubMed ID: 38335426
    [TBL] [Abstract][Full Text] [Related]  

  • 110. F-18 FDG PET/CT in staging and response assessment of primary cutaneous diffuse large B-cell lymphoma (leg type).
    Datta D; Pandey RR; Kumar R; Sharma R; Vedant D
    Eur J Hybrid Imaging; 2023 Aug; 7(1):15. PubMed ID: 37605015
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Diffuse Large B-cell Lymphoma (Leg Type) Originating in the Skin of the Right Cheek Region: A Case Report and Literature Review.
    Wei Y; Liu L; Bu L; Zhan X; Xu H; Wang S
    Ear Nose Throat J; 2023 Sep; ():1455613231202192. PubMed ID: 37776289
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-Cell Lymphoma, Leg-Type: A Case Report.
    Zoli S; Pellegrini C; Casadei B; Broccoli A; Argnani L; Nanni L; Stefoni V; Zinzani PL
    Chemotherapy; 2024; 69(1):23-26. PubMed ID: 37913761
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Primary Cutaneous B-cell Lymphomas: Case Report of Two Cases.
    Mishra S; Shelly D; Vinu Balraam KV; Bharadwaj R
    Indian J Dermatol; 2017; 62(6):675. PubMed ID: 29263552
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg type.
    Al Dhafiri M; Sicre de Fontbrune F; Marinho E; Deschamps L; Di-Lucca J; Crickx B; Descamps V
    Clin Case Rep; 2019 May; 7(5):964-967. PubMed ID: 31110725
    [TBL] [Abstract][Full Text] [Related]  

  • 115. The Molecular Landscape of Primary CNS Lymphomas (PCNSLs) in Children and Young Adults.
    Shi ZF; Li KK; Liu AP; Chung NY; Wong SC; Chen H; Woo PY; Chan DT; Mao Y; Ng HK
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730692
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Defining an Optimized Workflow for Enriching and Analyzing Residual Tumor Populations Using Intracellular Markers.
    Coulter EM; Bewicke-Copley F; Mossner M; Graham TA; Fitzgibbon J; Okosun J
    J Mol Diagn; 2024 Apr; 26(4):245-256. PubMed ID: 38280422
    [TBL] [Abstract][Full Text] [Related]  

  • 117. MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8.
    Mandato E; Yan Q; Ouyang J; Paczkowska J; Qin Y; Hao Y; Bojarczuk K; Hansen J; Chapuy B; Rodig SJ; Khan SJ; Redd RA; Shipp MA
    Blood; 2023 Oct; 142(14):1219-1232. PubMed ID: 37467575
    [TBL] [Abstract][Full Text] [Related]  

  • 118. [Clinicopathologic characteristics and prognostic analysis of testicular diffuse large B-cell lymphoma].
    Wang Y; Shi ZY; Shi Q; Wang S; Zhang MC; Shen R; He Y; Qiu HL; Yi HM; Dong L; Wang L; Cheng S; Xu PP; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):321-327. PubMed ID: 37357002
    [No Abstract]   [Full Text] [Related]  

  • 119. [Combination of zanubrutinib and rituximab in the treatment of primary cutaneous diffuse large B-cell lymphoma leg type with CD79B and MYD88 mutations: a case report].
    Zhong GC; Yu XN; Li J; Chen CY
    Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):258. PubMed ID: 37356991
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.